ReP USP - Resultado da busca

Trabalho de evento-resumo periodico
Metabolic adaptation and multidrug resistance in FLT3 inhibitor resistant acute myeloid leukemia (2025)
Miranda, Lívia Bassani Lins De ; Martins, Diego Antonio Pereira ; Ramos, Dominique Sternadt Alexandre ; Simões, Luíse Araújo de Albuquerque ; Lima, Keli ; Tomaz, Victoria ; Cortez, Luiz Ferreira; Silva, Mariana de Franca Basto; Guedes, Rafael Lucas Muniz ; Traina, Fabiola ; Campregher, Paulo Vidal ; Rego, Eduardo Magalhães ; Schuringa, Jan Jacob ; Machado Neto, João Agostinho
Source: FEBS Open Bio. Conference titles: Bridging Continents to Advance Life Science. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, MUTAÇÃO GENÉTICA, CÉLULAS CULTIVADAS DE TUMOR, APOPTOSE, PROTEÔMICA, ANTINEOPLÁSICOS, ESTRESSE OXIDATIVO, GLICOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MIRANDA, Lívia Bassani Lins De et al. Metabolic adaptation and multidrug resistance in FLT3 inhibitor resistant acute myeloid leukemia. FEBS Open Bio. Oxford: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/2211-5463.70071. Acesso em: 26 abr. 2026. , 2025
APA
Miranda, L. B. L. D., Martins, D. A. P., Ramos, D. S. A., Simões, L. A. de A., Lima, K., Tomaz, V., et al. (2025). Metabolic adaptation and multidrug resistance in FLT3 inhibitor resistant acute myeloid leukemia. FEBS Open Bio. Oxford: Faculdade de Medicina, Universidade de São Paulo. doi:10.1002/2211-5463.70071
NLM
Miranda LBLD, Martins DAP, Ramos DSA, Simões LA de A, Lima K, Tomaz V, Cortez LF, Silva M de FB, Guedes RLM, Traina F, Campregher PV, Rego EM, Schuringa JJ, Machado Neto JA. Metabolic adaptation and multidrug resistance in FLT3 inhibitor resistant acute myeloid leukemia [Internet]. FEBS Open Bio. 2025 ; 15 247-248.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1002/2211-5463.70071
Vancouver
Miranda LBLD, Martins DAP, Ramos DSA, Simões LA de A, Lima K, Tomaz V, Cortez LF, Silva M de FB, Guedes RLM, Traina F, Campregher PV, Rego EM, Schuringa JJ, Machado Neto JA. Metabolic adaptation and multidrug resistance in FLT3 inhibitor resistant acute myeloid leukemia [Internet]. FEBS Open Bio. 2025 ; 15 247-248.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1002/2211-5463.70071
Artigo de periodico
Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms (2025)
Pereira-Martins, Diego Antonio ; Alves-Silva, Antonio Bruno ; Melo, Manuela Albuquerque de ; Fonseca, Natasha Peixoto ; Weinhäuser, Isabel ; Perez, Fabio Augusto Bueno; Bellomi, Artur Bernardo Ribeiro; Figueiredo-Pontes, Lorena Lobo ; Quek,Lynn ; Chatzikyriakou, Prodomos ; Huls, Gerwin A. ; Ammatuna, Emanuele ; Schuringa, Jan Jacob ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Blood. Conference titles: The 66th ASH Annual Meeting Abstracts. Unidades: FMRP, ICB
Subjects: FARMACOLOGIA, DOENÇAS SANGUÍNEAS E LINFÁTICAS, MEDULA ÓSSEA, CÉLULAS SANGUÍNEAS, MUTAÇÃO GENÉTICA, CITOMETRIA DE FLUXO, CAMUNDONGOS, CÉLULAS MIELOIDES, LEUCEMIA MIELOIDE, NEOPLASIAS POR TIPO HISTOLÓGICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEREIRA-MARTINS, Diego Antonio et al. Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms. Blood, v. 144, p. 4518-4519, 2025Tradução . . Disponível em: https://doi.org/10.1182/blood-2024-209823. Acesso em: 26 abr. 2026.
APA
Pereira-Martins, D. A., Alves-Silva, A. B., Melo, M. A. de, Fonseca, N. P., Weinhäuser, I., Perez, F. A. B., et al. (2025). Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms. Blood, 144, 4518-4519. doi:10.1182/blood-2024-209823
NLM
Pereira-Martins DA, Alves-Silva AB, Melo MA de, Fonseca NP, Weinhäuser I, Perez FAB, Bellomi ABR, Figueiredo-Pontes LL, Quek L, Chatzikyriakou P, Huls GA, Ammatuna E, Schuringa JJ, Traina F, Machado Neto JA. Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms [Internet]. Blood. 2025 ; 144 4518-4519.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2024-209823
Vancouver
Pereira-Martins DA, Alves-Silva AB, Melo MA de, Fonseca NP, Weinhäuser I, Perez FAB, Bellomi ABR, Figueiredo-Pontes LL, Quek L, Chatzikyriakou P, Huls GA, Ammatuna E, Schuringa JJ, Traina F, Machado Neto JA. Synergistic effect of tamoxifen and ruxolitinib combination in reducing disease burden in myeloproliferative neoplasms [Internet]. Blood. 2025 ; 144 4518-4519.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2024-209823
Trabalho de evento-resumo periodico
Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors (2024)
Melo, Manuela Albuquerque de ; Pereira-Martins, Diego Antonio ; Macedo, Brunno Gilberto Santos ; Miranda, Lívia Bassani Lins De ; Scheucher, Priscila Santos ; Weinhäuser, Isabel ; Huls, Gerwin A. ; Schuringa, Jan Jacob ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Blood. Conference titles: The 66th ASH Annual Meeting. Unidades: FMRP, ICB
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, ANTIMALÁRICOS, MITOCÔNDRIAS, PROTEÔMICA, CAMUNDONGOS, LINHAGEM CELULAR, SOBREVIVÊNCIA CELULAR, ESTUDOS DE COORTES, PROLIFERAÇÃO CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MELO, Manuela Albuquerque de et al. Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors. Blood. Washington, DC: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2024-203390. Acesso em: 26 abr. 2026. , 2024
APA
Melo, M. A. de, Pereira-Martins, D. A., Macedo, B. G. S., Miranda, L. B. L. D., Scheucher, P. S., Weinhäuser, I., et al. (2024). Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors. Blood. Washington, DC: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2024-203390
NLM
Melo MA de, Pereira-Martins DA, Macedo BGS, Miranda LBLD, Scheucher PS, Weinhäuser I, Huls GA, Schuringa JJ, Traina F, Machado Neto JA. Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors [Internet]. Blood. 2024 ; 144( supl. 1): 2752-2753.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2024-203390
Vancouver
Melo MA de, Pereira-Martins DA, Macedo BGS, Miranda LBLD, Scheucher PS, Weinhäuser I, Huls GA, Schuringa JJ, Traina F, Machado Neto JA. Molecular mechanisms associated with autophagy inhibition to overcome resistance to FLT3 inhibitors [Internet]. Blood. 2024 ; 144( supl. 1): 2752-2753.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2024-203390
Artigo de periodico
Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia (2024)
Lima, Keli ; Nogueira, Frederico Lisboa ; Cipelli, Marcella ; Carvalho, Maria Fernanda Lopes ; Martins, Diego Antonio Pereira ; Silva, Wellington Fernandes da ; Medeiros, Rita de Cássia Cavaglieri ; Nardinelli, Luciana ; Leal, Aline de Medeiros; Velloso, Elvira Deolinda Rodrigues Pereira ; Bendit, Israel ; Camara, Niels Olsen Saraiva ; Schuringa, Jan Jacob ; Machado Neto, João Agostinho ; Rego, Eduardo Magalhães
Source: European Journal of Pharmacology. Unidades: FM, ICB
Subjects: FARMACOLOGIA, IMUNOLOGIA, ANTINEOPLÁSICOS, SOBREVIVÊNCIA CELULAR, INIBIDORES DE ENZIMAS, PROTEÍNAS QUINASES, PROTEÍNAS PROTO-ONCOGÊNICAS, NEOPLASIAS POR TIPO HISTOLÓGICO, LEUCEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli et al. Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia. European Journal of Pharmacology, v. 977, p. 11 , 2024Tradução . . Disponível em: https://doi.org/10.1016/j.ejphar.2024.176723. Acesso em: 26 abr. 2026.
APA
Lima, K., Nogueira, F. L., Cipelli, M., Carvalho, M. F. L., Martins, D. A. P., Silva, W. F. da, et al. (2024). Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia. European Journal of Pharmacology, 977, 11 . doi:10.1016/j.ejphar.2024.176723
NLM
Lima K, Nogueira FL, Cipelli M, Carvalho MFL, Martins DAP, Silva WF da, Medeiros R de CC, Nardinelli L, Leal A de M, Velloso EDRP, Bendit I, Camara NOS, Schuringa JJ, Machado Neto JA, Rego EM. Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia [Internet]. European Journal of Pharmacology. 2024 ; 977 11 .[citado 2026 abr. 26 ] Available from: https://doi.org/10.1016/j.ejphar.2024.176723
Vancouver
Lima K, Nogueira FL, Cipelli M, Carvalho MFL, Martins DAP, Silva WF da, Medeiros R de CC, Nardinelli L, Leal A de M, Velloso EDRP, Bendit I, Camara NOS, Schuringa JJ, Machado Neto JA, Rego EM. Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia [Internet]. European Journal of Pharmacology. 2024 ; 977 11 .[citado 2026 abr. 26 ] Available from: https://doi.org/10.1016/j.ejphar.2024.176723
Artigo de periodico-carta/editorial
Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia. [Carta] (2024)
Salustiano-Bandeira, Maria L.; Moreira-Aguiar, Amanda; Martins, Diego Antonio Pereira; Coelho-Silva, Juan Luiz ; Weinhauser, Isabel; Franca-Neto, Pedro L.; Lima, Aleide S.; Yamada, Ana Silvia Gouvêa; Baccarin, Anemari R. D.; Silva, Fernanda B.; Melo, Manuela Albuquerque de ; Niemann, Fernanda Soares; Nardinelli, Luciana ; Rojas, César Alexander Ortiz ; Duarte, Bruno K.; Araújo, Aderson S.; Azevedo, Elisa A.; Morais, Clarice N.; Figueiredo-Pontes, Lorena Lobo ; Schuringa, Jan Jacob; Huls, Gerwin A.; Bendit, Israel ; Rego, Eduardo Magalhães ; Saad, Sara Teresinha Olalla; Traina, Fabiola ; Bezerra, Marcos A.; Lucena-Araújo, Antonio Roberto
Source: Blood Cancer Journal. Unidades: FMRP, FM
Subjects: REGULAÇÃO GÊNICA, LEUCEMIA MIELOIDE AGUDA, PROTEÍNAS NUCLEARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SALUSTIANO-BANDEIRA, Maria L. et al. Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia. [Carta]. Blood Cancer Journal. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1038/s41408-024-01086-8. Acesso em: 26 abr. 2026. , 2024
APA
Salustiano-Bandeira, M. L., Moreira-Aguiar, A., Martins, D. A. P., Coelho-Silva, J. L., Weinhauser, I., Franca-Neto, P. L., et al. (2024). Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia. [Carta]. Blood Cancer Journal. London: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1038/s41408-024-01086-8
NLM
Salustiano-Bandeira ML, Moreira-Aguiar A, Martins DAP, Coelho-Silva JL, Weinhauser I, Franca-Neto PL, Lima AS, Yamada ASG, Baccarin ARD, Silva FB, Melo MA de, Niemann FS, Nardinelli L, Rojas CAO, Duarte BK, Araújo AS, Azevedo EA, Morais CN, Figueiredo-Pontes LL, Schuringa JJ, Huls GA, Bendit I, Rego EM, Saad STO, Traina F, Bezerra MA, Lucena-Araújo AR. Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia. [Carta] [Internet]. Blood Cancer Journal. 2024 ; 14( 1): 1-3.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1038/s41408-024-01086-8
Vancouver
Salustiano-Bandeira ML, Moreira-Aguiar A, Martins DAP, Coelho-Silva JL, Weinhauser I, Franca-Neto PL, Lima AS, Yamada ASG, Baccarin ARD, Silva FB, Melo MA de, Niemann FS, Nardinelli L, Rojas CAO, Duarte BK, Araújo AS, Azevedo EA, Morais CN, Figueiredo-Pontes LL, Schuringa JJ, Huls GA, Bendit I, Rego EM, Saad STO, Traina F, Bezerra MA, Lucena-Araújo AR. Prognostic implications of ΔNp73/TAp73 expression ratio in core-binding factor acute myeloid leukemia. [Carta] [Internet]. Blood Cancer Journal. 2024 ; 14( 1): 1-3.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1038/s41408-024-01086-8
Trabalho de evento-resumo periodico
Pharmacological PIP4K2 inhibition disrupts mitochondrial homeostasis and autophagy in acute leukemia (2023)
Lima, Keli ; Pereira-Martins, Diego Antonio ; Miranda, Lívia Bassani Lins de ; Coelho-Silva, Juan Luiz ; Cavaglieri, Rita de Cássia ; Schuringa, Jan Jacob ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho
Source: Molecular Biology of the Cell. Conference titles: Annual Meeting of the American Society for Cell Biology (ASCB) and the European Molecular Biology Organization (EMBO). Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, MITOCÔNDRIAS, HOMEOSTASE, LEUCEMIA MIELOIDE AGUDA, ANTINEOPLÁSICOS, APOPTOSE, WESTERN BLOTTING, REAÇÃO EM CADEIA POR POLIMERASE, NEOPLASIAS POR TIPO HISTOLÓGICO, CÉLULAS CULTIVADAS DE TUMOR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli et al. Pharmacological PIP4K2 inhibition disrupts mitochondrial homeostasis and autophagy in acute leukemia. Molecular Biology of the Cell. Bethesda, MD: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1091/mbc.E22-12-0555. Acesso em: 26 abr. 2026. , 2023
APA
Lima, K., Pereira-Martins, D. A., Miranda, L. B. L. de, Coelho-Silva, J. L., Cavaglieri, R. de C., Schuringa, J. J., et al. (2023). Pharmacological PIP4K2 inhibition disrupts mitochondrial homeostasis and autophagy in acute leukemia. Molecular Biology of the Cell. Bethesda, MD: Faculdade de Medicina, Universidade de São Paulo. doi:10.1091/mbc.E22-12-0555
NLM
Lima K, Pereira-Martins DA, Miranda LBL de, Coelho-Silva JL, Cavaglieri R de C, Schuringa JJ, Rego EM, Machado Neto JA. Pharmacological PIP4K2 inhibition disrupts mitochondrial homeostasis and autophagy in acute leukemia [Internet]. Molecular Biology of the Cell. 2023 ; 34( 2): 166-167.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1091/mbc.E22-12-0555
Vancouver
Lima K, Pereira-Martins DA, Miranda LBL de, Coelho-Silva JL, Cavaglieri R de C, Schuringa JJ, Rego EM, Machado Neto JA. Pharmacological PIP4K2 inhibition disrupts mitochondrial homeostasis and autophagy in acute leukemia [Internet]. Molecular Biology of the Cell. 2023 ; 34( 2): 166-167.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1091/mbc.E22-12-0555
Artigo de periodico
Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia (2023)
Lima, Keli ; Carvalho, Maria Fernanda Lopes ; Martins, Diego Antonio Pereira ; Silva, Wellington Fernandes da; Nascimento, Mariane Cristina do ; Miranda, Lívia Bassani Lins De ; Medeiros, Rita de Cássia Cavaglieri ; Nardinelli, Luciana; Leal, Aline de Medeiros; Velloso, Elvira Deolinda Rodrigues Pereira ; Bendit, Israel ; Schuringa, Jan Jacob ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho
Source: Blood. Conference titles: 65th ASH Annual Meeting Abstracts. Unidades: FM, ICB, FMRP
Subjects: HEMATOLOGIA, LEUCEMIA, LINFOMA, DOENÇAS SANGUÍNEAS E LINFÁTICAS, INIBIDORES QUÍMICOS, ESTUDOS DE COORTES, EXPRESSÃO GÊNICA, REAÇÃO EM CADEIA POR POLIMERASE, WESTERN BLOTTING, CITOMETRIA DE FLUXO, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli et al. Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia. Blood, v. 142, p. 5886, 2023Tradução . . Disponível em: https://doi.org/10.1182/blood-2023-189786. Acesso em: 26 abr. 2026.
APA
Lima, K., Carvalho, M. F. L., Martins, D. A. P., Silva, W. F. da, Nascimento, M. C. do, Miranda, L. B. L. D., et al. (2023). Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia. Blood, 142, 5886. doi:10.1182/blood-2023-189786
NLM
Lima K, Carvalho MFL, Martins DAP, Silva WF da, Nascimento MC do, Miranda LBLD, Medeiros R de CC, Nardinelli L, Leal A de M, Velloso EDRP, Bendit I, Schuringa JJ, Rego EM, Machado Neto JA. Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia [Internet]. Blood. 2023 ; 142 5886.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2023-189786
Vancouver
Lima K, Carvalho MFL, Martins DAP, Silva WF da, Nascimento MC do, Miranda LBLD, Medeiros R de CC, Nardinelli L, Leal A de M, Velloso EDRP, Bendit I, Schuringa JJ, Rego EM, Machado Neto JA. Potency and efficacy of pharmacological PIP4K2 inhibitors in acute lymphoblastic leukemia [Internet]. Blood. 2023 ; 142 5886.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2023-189786
Artigo de periodico
Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models (2023)
Nascimento, Mariane Cristina do ; Martins, Diego Antonio Pereira ; Alcântara, Guilherme Augusto Sousa; Lima, Keli ; Vicari, Hugo Passos ; Huls, Gerwin A. ; Schuringa, Jan Jacob ; Rego, Eduardo Magalhães ; Ferreira, Marcelo José Pena ; Costa-Lotufo, Letícia Veras ; Machado Neto, João Agostinho
Source: Blood. Conference titles: 65th ASH Annual Meeting Abstracts. Unidades: IB, FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, HEMATOLOGIA, QUIMIOTERAPIA COMBINADA, CÉLULAS CULTIVADAS DE TUMOR, PROLIFERAÇÃO CELULAR, NEOPLASIAS POR TIPO HISTOLÓGICO, APOPTOSE, DANO AO DNA, MITOCÔNDRIAS, PROTEÔMICA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NASCIMENTO, Mariane Cristina do et al. Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models. Blood, v. 142, n. res. 604, p. 5751, 2023Tradução . . Disponível em: https://doi.org/10.1182/blood-2023-189814. Acesso em: 26 abr. 2026.
APA
Nascimento, M. C. do, Martins, D. A. P., Alcântara, G. A. S., Lima, K., Vicari, H. P., Huls, G. A., et al. (2023). Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models. Blood, 142( res. 604), 5751. doi:10.1182/blood-2023-189814
NLM
Nascimento MC do, Martins DAP, Alcântara GAS, Lima K, Vicari HP, Huls GA, Schuringa JJ, Rego EM, Ferreira MJP, Costa-Lotufo LV, Machado Neto JA. Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models [Internet]. Blood. 2023 ; 142( res. 604): 5751.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2023-189814
Vancouver
Nascimento MC do, Martins DAP, Alcântara GAS, Lima K, Vicari HP, Huls GA, Schuringa JJ, Rego EM, Ferreira MJP, Costa-Lotufo LV, Machado Neto JA. Cephalochromin-induced mitochondrial damage overcomes venetoclax-resistance in acute Myeloid Leukemia Models [Internet]. Blood. 2023 ; 142( res. 604): 5751.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2023-189814
Artigo de periodico
Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia (2023)
Lima, Keli ; Carvalho, Maria Fernanda Lopes ; Martins, Diego Antonio Pereira ; Nascimento, Mariane Cristina do ; Nogueira, Frederico Lisboa ; Medeiros, Rita de Cássia Cavaglieri ; Schuringa, Jan Jacob ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho
Source: Blood. Conference titles: 65th ASH Annual Meeting Abstracts. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, HEMATOLOGIA, LEUCEMIA MIELOIDE AGUDA, QUIMIOTERAPIA COMBINADA, CÉLULAS CULTIVADAS DE TUMOR, PROLIFERAÇÃO CELULAR, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTINEOPLÁSICOS, PROTEÍNAS, CÉLULAS MIELOIDES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli et al. Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia. Blood, v. 142, n. Supl. 1, p. 5774, 2023Tradução . . Disponível em: https://doi.org/10.1182/blood-2023-189998. Acesso em: 26 abr. 2026.
APA
Lima, K., Carvalho, M. F. L., Martins, D. A. P., Nascimento, M. C. do, Nogueira, F. L., Medeiros, R. de C. C., et al. (2023). Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia. Blood, 142( Supl. 1), 5774. doi:10.1182/blood-2023-189998
NLM
Lima K, Carvalho MFL, Martins DAP, Nascimento MC do, Nogueira FL, Medeiros R de CC, Schuringa JJ, Rego EM, Machado Neto JA. Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia [Internet]. Blood. 2023 ; 142( Supl. 1): 5774.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2023-189998
Vancouver
Lima K, Carvalho MFL, Martins DAP, Nascimento MC do, Nogueira FL, Medeiros R de CC, Schuringa JJ, Rego EM, Machado Neto JA. Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia [Internet]. Blood. 2023 ; 142( Supl. 1): 5774.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2023-189998
Artigo de periodico
Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia (2023)
Lima, Keli ; Carvalho, Maria Fernanda Lopes ; Pereira-Martins, Diego Antonio ; Nogueira, Frederico Lisboa ; Miranda, Lívia Bassani Lins de ; Mariane Cristina do Nascimento ; Cavaglieri, Rita de Cássia ; Schuringa, Jan Jacob ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho
Source: International Journal of Molecular Sciences. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTINEOPLÁSICOS, APOPTOSE, PROTEÍNAS PROTO-ONCOGÊNICAS, COMPOSTOS HETEROCÍCLICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli et al. Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia. International Journal of Molecular Sciences, v. 24, n. 23, p. 12 , 2023Tradução . . Disponível em: https://doi.org/10.3390/ijms242316899. Acesso em: 26 abr. 2026.
APA
Lima, K., Carvalho, M. F. L., Pereira-Martins, D. A., Nogueira, F. L., Miranda, L. B. L. de, Mariane Cristina do Nascimento,, et al. (2023). Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 24( 23), 12 . doi:10.3390/ijms242316899
NLM
Lima K, Carvalho MFL, Pereira-Martins DA, Nogueira FL, Miranda LBL de, Mariane Cristina do Nascimento, Cavaglieri R de C, Schuringa JJ, Rego EM, Machado Neto JA. Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia [Internet]. International Journal of Molecular Sciences. 2023 ; 24( 23): 12 .[citado 2026 abr. 26 ] Available from: https://doi.org/10.3390/ijms242316899
Vancouver
Lima K, Carvalho MFL, Pereira-Martins DA, Nogueira FL, Miranda LBL de, Mariane Cristina do Nascimento, Cavaglieri R de C, Schuringa JJ, Rego EM, Machado Neto JA. Pharmacological inhibition of PIP4K2 potentiates venetoclax-induced apoptosis in Acute Myeloid Leukemia [Internet]. International Journal of Molecular Sciences. 2023 ; 24( 23): 12 .[citado 2026 abr. 26 ] Available from: https://doi.org/10.3390/ijms242316899
Artigo de periodico
Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia (2022)
Lima, Keli ; Pereira-Martins Diego A. ; Miranda, Lívia Bassani Lins de ; Coelho-Silva, Juan Luiz ; Leandro, Giovana da Silva ; Isabel Weinhäuser ; Cavaglieri, Rita de Cássia ; Silva, Wellington F.; Leal, Aline Medeiros; Lange, Ana Paula Alencar de Lima; Velloso, Elvira Deolinda Rodrigues Pereira ; Griessinger, Emmanuel ; Hilberink, Jacobien R. ; Huls, Gerwin A. ; Schuringa, Jan Jacob ; Rego, Eduardo M. ; Machado Neto, João Agostinho
Source: Blood. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, AMINOÁCIDOS, PROTEÍNAS QUINASES, DANO AO DNA, MITOCÔNDRIAS, HOMEOSTASE, LISOSSOMOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli et al. Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia. Blood, v. 140, p. 5965–5966, 2022Tradução . . Disponível em: https://doi.org/10.1182/blood-2022-165172. Acesso em: 26 abr. 2026.
APA
Lima, K., Pereira-Martins Diego A.,, Miranda, L. B. L. de, Coelho-Silva, J. L., Leandro, G. da S., Isabel Weinhäuser,, et al. (2022). Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia. Blood, 140, 5965–5966. doi:10.1182/blood-2022-165172
NLM
Lima K, Pereira-Martins Diego A., Miranda LBL de, Coelho-Silva JL, Leandro G da S, Isabel Weinhäuser, Cavaglieri R de C, Silva WF, Leal AM, Lange APA de L, Velloso EDRP, Griessinger E, Hilberink JR, Huls GA, Schuringa JJ, Rego EM, Machado Neto JA. Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia [Internet]. Blood. 2022 ; 140 5965–5966.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2022-165172
Vancouver
Lima K, Pereira-Martins Diego A., Miranda LBL de, Coelho-Silva JL, Leandro G da S, Isabel Weinhäuser, Cavaglieri R de C, Silva WF, Leal AM, Lange APA de L, Velloso EDRP, Griessinger E, Hilberink JR, Huls GA, Schuringa JJ, Rego EM, Machado Neto JA. Targeting PIP4K2 lipid kinases through Thz-P1-2 reveals vulnerabilities related to mitochondrial homeostasis and autophagy in acute leukemia [Internet]. Blood. 2022 ; 140 5965–5966.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2022-165172
Trabalho de evento-resumo periodico
M2 macrophages drive resistance to phagocytosis and improve mitochondrial metabolism in acute myeloid leukemia facilitating leukemic transformation and in vivo engraftment (2022)
Weinhaeuser, Isabel; Pereira-Martins, Diego Antonio; Almeida, Luciana Yamamoto de ; Hilberink, Jacobien R.; Silveira, Douglas Rafaele Almeida ; Quek, Lynn; Ortiz, César Alexander; Lucena-Araújo, Antonio Roberto; Araujo, Cleide L.; Bianco, Thiago Mantello ; Mota, Jose Mauricio; Hogeling, Shanna M.; Sternadt, Dominique; Diepstra, Arjan; Visser, Nienke; Ammatuna, Emanuele; Huls, Gerwin A.; Rego, Eduardo Magalhães ; Schuringa, Jan Jacob
Source: Blood. Conference titles: ASH Annual Meeting and Exposition. Unidades: FM, FMRP
Subjects: MACRÓFAGOS, FAGOCITOSE, LEUCEMIA MIELOIDE AGUDA, EXPRESSÃO GÊNICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WEINHAEUSER, Isabel et al. M2 macrophages drive resistance to phagocytosis and improve mitochondrial metabolism in acute myeloid leukemia facilitating leukemic transformation and in vivo engraftment. Blood. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2022-165130. Acesso em: 26 abr. 2026. , 2022
APA
Weinhaeuser, I., Pereira-Martins, D. A., Almeida, L. Y. de, Hilberink, J. R., Silveira, D. R. A., Quek, L., et al. (2022). M2 macrophages drive resistance to phagocytosis and improve mitochondrial metabolism in acute myeloid leukemia facilitating leukemic transformation and in vivo engraftment. Blood. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. doi:10.1182/blood-2022-165130
NLM
Weinhaeuser I, Pereira-Martins DA, Almeida LY de, Hilberink JR, Silveira DRA, Quek L, Ortiz CA, Lucena-Araújo AR, Araujo CL, Bianco TM, Mota JM, Hogeling SM, Sternadt D, Diepstra A, Visser N, Ammatuna E, Huls GA, Rego EM, Schuringa JJ. M2 macrophages drive resistance to phagocytosis and improve mitochondrial metabolism in acute myeloid leukemia facilitating leukemic transformation and in vivo engraftment [Internet]. Blood. 2022 ; 140( suppl. 1): 1259-1260.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2022-165130
Vancouver
Weinhaeuser I, Pereira-Martins DA, Almeida LY de, Hilberink JR, Silveira DRA, Quek L, Ortiz CA, Lucena-Araújo AR, Araujo CL, Bianco TM, Mota JM, Hogeling SM, Sternadt D, Diepstra A, Visser N, Ammatuna E, Huls GA, Rego EM, Schuringa JJ. M2 macrophages drive resistance to phagocytosis and improve mitochondrial metabolism in acute myeloid leukemia facilitating leukemic transformation and in vivo engraftment [Internet]. Blood. 2022 ; 140( suppl. 1): 1259-1260.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2022-165130
Artigo de periodico
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy (2022)
Lima, Keli ; Martins, Diego Antonio Pereira ; Miranda, Lívia Bassani Lins De ; Silva, Juan Luiz Coelho ; Leandro, Giovana da Silva ; Weinhäuser, Isabel ; Cavaglieri, Rita de Cássia; Leal, Aline de Medeiros; Silva, Wellington Fernandes da; Lange, Ana Paula Alencar de Lima; Velloso, Elvira Deolinda Rodrigues Pereira ; Rego, Eduardo Magalhães ; Griessinger, Emmanuel ; Hilberink, Jacobien R. ; Ammatuna, Emanuele ; Huls, Gerwin ; Schuringa, Jan Jacob ; Machado Neto, João Agostinho
Source: Blood Cancer Journal. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, HOMEOSTASE, APOPTOSE, MITOCÔNDRIAS, ESPECTROMETRIA DE MASSAS, CROMATOGRAFIA LÍQUIDA, CÉLULAS-TRONCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli et al. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy. Blood Cancer Journal, v. 12, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41408-022-00747-w. Acesso em: 26 abr. 2026.
APA
Lima, K., Martins, D. A. P., Miranda, L. B. L. D., Silva, J. L. C., Leandro, G. da S., Weinhäuser, I., et al. (2022). The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy. Blood Cancer Journal, 12, 1-11. doi:10.1038/s41408-022-00747-w
NLM
Lima K, Martins DAP, Miranda LBLD, Silva JLC, Leandro G da S, Weinhäuser I, Cavaglieri R de C, Leal A de M, Silva WF da, Lange APA de L, Velloso EDRP, Rego EM, Griessinger E, Hilberink JR, Ammatuna E, Huls G, Schuringa JJ, Machado Neto JA. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy [Internet]. Blood Cancer Journal. 2022 ; 12 1-11.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1038/s41408-022-00747-w
Vancouver
Lima K, Martins DAP, Miranda LBLD, Silva JLC, Leandro G da S, Weinhäuser I, Cavaglieri R de C, Leal A de M, Silva WF da, Lange APA de L, Velloso EDRP, Rego EM, Griessinger E, Hilberink JR, Ammatuna E, Huls G, Schuringa JJ, Machado Neto JA. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy [Internet]. Blood Cancer Journal. 2022 ; 12 1-11.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1038/s41408-022-00747-w
Artigo de periodico
The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells (2021)
Almeida, Luciana Yamamoto de; Martins, Diego A. Pereira; Weinhäuser, Isabel; Ortiz, César; Cândido, Larissa A.; Lange, Ana Paula; Abreu, Nayara F. de; Mendonza, Sílvia E. S.; Wagatsuma, Virgínia M. de Deus; Nascimento, Mariane C. do; Paiva, Helder H.; Alves-Paiva, Raquel M.; Bonaldo, Camila C. O. M.; Nascimento, Daniele C.; Alves-Filho, José Carlos; Scheucher, Priscila S.; Lima, Ana Silvia Gouvêa de; Schuringa, Jan Jacob; Ammantuna, Emanuele; Ottone, Tiziana; Noguera, Nelida I.; Araujo, Cleide L.; Rego, Eduardo M.
Source: Frontiers in Oncology. Unidades: FMRP, FM
Subjects: LEUCEMIA, CÉLULAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ALMEIDA, Luciana Yamamoto de et al. The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells. Frontiers in Oncology, v. 11, 2021Tradução . . Disponível em: https://doi.org/10.3389/fonc.2021.686445. Acesso em: 26 abr. 2026.
APA
Almeida, L. Y. de, Martins, D. A. P., Weinhäuser, I., Ortiz, C., Cândido, L. A., Lange, A. P., et al. (2021). The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells. Frontiers in Oncology, 11. doi:10.3389/fonc.2021.686445
NLM
Almeida LY de, Martins DAP, Weinhäuser I, Ortiz C, Cândido LA, Lange AP, Abreu NF de, Mendonza SES, Wagatsuma VM de D, Nascimento MC do, Paiva HH, Alves-Paiva RM, Bonaldo CCOM, Nascimento DC, Alves-Filho JC, Scheucher PS, Lima ASG de, Schuringa JJ, Ammantuna E, Ottone T, Noguera NI, Araujo CL, Rego EM. The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells [Internet]. Frontiers in Oncology. 2021 ; 11[citado 2026 abr. 26 ] Available from: https://doi.org/10.3389/fonc.2021.686445
Vancouver
Almeida LY de, Martins DAP, Weinhäuser I, Ortiz C, Cândido LA, Lange AP, Abreu NF de, Mendonza SES, Wagatsuma VM de D, Nascimento MC do, Paiva HH, Alves-Paiva RM, Bonaldo CCOM, Nascimento DC, Alves-Filho JC, Scheucher PS, Lima ASG de, Schuringa JJ, Ammantuna E, Ottone T, Noguera NI, Araujo CL, Rego EM. The combination of gefitinib with ATRA and ATO induces myeloid differentiation in acute promyelocytic leukemia resistant cells [Internet]. Frontiers in Oncology. 2021 ; 11[citado 2026 abr. 26 ] Available from: https://doi.org/10.3389/fonc.2021.686445
Artigo de periodico
The expression of NTAL and its protein interactors is associated with clinical outcomes in acute myeloid leukemia (2021)
Thomé, Carolina Hassibe; Ferreira, Germano Aguiar; Pereira-Martins, Diego Antonio; Santos, Guilherme Augusto dos; Almeida-Silveira, Douglas R.; Weinhäuser, Isabel; Souza, Gustavo Antonio de; Houtsma, Roos; Schuringa, Jan Jacob; Rego, Eduardo Magalhães; Faça, Vitor Marcel
Source: Molecular and Cellular Proteomics. Unidades: FMRP, FM
Subjects: TRANSDUÇÃO DE SINAL CELULAR, LINHAGEM CELULAR, LEUCEMIA MIELOIDE AGUDA, PROLIFERAÇÃO CELULAR, PROTEÍNAS PROTO-ONCOGÊNICAS, ANÁLISE DE SOBREVIVÊNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
THOMÉ, Carolina Hassibe et al. The expression of NTAL and its protein interactors is associated with clinical outcomes in acute myeloid leukemia. Molecular and Cellular Proteomics, v. 20, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.mcpro.2021.100091. Acesso em: 26 abr. 2026.
APA
Thomé, C. H., Ferreira, G. A., Pereira-Martins, D. A., Santos, G. A. dos, Almeida-Silveira, D. R., Weinhäuser, I., et al. (2021). The expression of NTAL and its protein interactors is associated with clinical outcomes in acute myeloid leukemia. Molecular and Cellular Proteomics, 20. doi:10.1016/j.mcpro.2021.100091
NLM
Thomé CH, Ferreira GA, Pereira-Martins DA, Santos GA dos, Almeida-Silveira DR, Weinhäuser I, Souza GA de, Houtsma R, Schuringa JJ, Rego EM, Faça VM. The expression of NTAL and its protein interactors is associated with clinical outcomes in acute myeloid leukemia [Internet]. Molecular and Cellular Proteomics. 2021 ; 20[citado 2026 abr. 26 ] Available from: https://doi.org/10.1016/j.mcpro.2021.100091
Vancouver
Thomé CH, Ferreira GA, Pereira-Martins DA, Santos GA dos, Almeida-Silveira DR, Weinhäuser I, Souza GA de, Houtsma R, Schuringa JJ, Rego EM, Faça VM. The expression of NTAL and its protein interactors is associated with clinical outcomes in acute myeloid leukemia [Internet]. Molecular and Cellular Proteomics. 2021 ; 20[citado 2026 abr. 26 ] Available from: https://doi.org/10.1016/j.mcpro.2021.100091
Trabalho de evento-resumo periodico
Tumor associated macrophages promoted fatal patient derived acute promyelocytic leukemia in vivo (2021)
Weinhäuser, Isabel ; Martins, Diego A. Pereira; Hilberink, Jacobien R.; Almeida, Luciana Yamamoto de ; Silveira, Douglas Rafaele Almeida ; Quek, Lynn; Hogeling, Shanna M.; Mota, Jose Mauricio; Ammatuna, Emanuele; Araujo, Antônio Roberto Lucena de ; Huls, Gerwin A.; Schuringa, Jan Jacob; Rego, Eduardo Magalhães
Source: Blood. Conference titles: ASH Annual Meeting and Exposition. Unidades: FM, FMRP
Subjects: MACRÓFAGOS, TUMOR CARCINOIDE, MARCADOR MOLECULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WEINHÄUSER, Isabel et al. Tumor associated macrophages promoted fatal patient derived acute promyelocytic leukemia in vivo. Blood. Atlanta: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2021-150699. Acesso em: 26 abr. 2026. , 2021
APA
Weinhäuser, I., Martins, D. A. P., Hilberink, J. R., Almeida, L. Y. de, Silveira, D. R. A., Quek, L., et al. (2021). Tumor associated macrophages promoted fatal patient derived acute promyelocytic leukemia in vivo. Blood. Atlanta: Faculdade de Medicina, Universidade de São Paulo. doi:10.1182/blood-2021-150699
NLM
Weinhäuser I, Martins DAP, Hilberink JR, Almeida LY de, Silveira DRA, Quek L, Hogeling SM, Mota JM, Ammatuna E, Araujo ARL de, Huls GA, Schuringa JJ, Rego EM. Tumor associated macrophages promoted fatal patient derived acute promyelocytic leukemia in vivo [Internet]. Blood. 2021 ; 138 3472.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2021-150699
Vancouver
Weinhäuser I, Martins DAP, Hilberink JR, Almeida LY de, Silveira DRA, Quek L, Hogeling SM, Mota JM, Ammatuna E, Araujo ARL de, Huls GA, Schuringa JJ, Rego EM. Tumor associated macrophages promoted fatal patient derived acute promyelocytic leukemia in vivo [Internet]. Blood. 2021 ; 138 3472.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2021-150699
Artigo de periodico
MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model (2021)
Pereira-Martins, Diego Antonio ; Weinhäuser, Isabel ; Coelho-Silva, Juan Luiz ; Franca-Neto, Pedro L.; Almeida, Luciana Y.; Bianco, Thiago Mantello ; Silva, Cleide L.; Franca, Rafael Freitas de Oliveira ; Traina, Fabiola ; Rego, Eduardo Magalhães ; Schuringa, Jan Jacob ; Lucena-Araújo, Antonio Roberto
Source: Cell Death & Disease. Unidades: FMRP, FM
Subjects: ANTINEOPLÁSICOS, APOPTOSE, DIFERENCIAÇÃO CELULAR, PROLIFERAÇÃO CELULAR, LEUCEMIA, FATORES DE TRANSCRIÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PEREIRA-MARTINS, Diego Antonio et al. MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model. Cell Death & Disease, v. 12, n. 4, p. 1-14, 2021Tradução . . Disponível em: https://doi.org/10.1038/s41419-021-03604-z. Acesso em: 26 abr. 2026.
APA
Pereira-Martins, D. A., Weinhäuser, I., Coelho-Silva, J. L., Franca-Neto, P. L., Almeida, L. Y., Bianco, T. M., et al. (2021). MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model. Cell Death & Disease, 12( 4), 1-14. doi:10.1038/s41419-021-03604-z
NLM
Pereira-Martins DA, Weinhäuser I, Coelho-Silva JL, Franca-Neto PL, Almeida LY, Bianco TM, Silva CL, Franca RF de O, Traina F, Rego EM, Schuringa JJ, Lucena-Araújo AR. MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model [Internet]. Cell Death & Disease. 2021 ; 12( 4): 1-14.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1038/s41419-021-03604-z
Vancouver
Pereira-Martins DA, Weinhäuser I, Coelho-Silva JL, Franca-Neto PL, Almeida LY, Bianco TM, Silva CL, Franca RF de O, Traina F, Rego EM, Schuringa JJ, Lucena-Araújo AR. MLL5 improves ATRA driven differentiation and promotes xenotransplant engraftment in acute promyelocytic leukemia model [Internet]. Cell Death & Disease. 2021 ; 12( 4): 1-14.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1038/s41419-021-03604-z
Trabalho de evento-resumo periodico
Clinical Signicance of Mitochondrial DNA Content in Acute Promyelocytic Leukemi (2021)
Araujo, Antônio Roberto Lucena de ; Martins, Diego Antonio Pereira ; Silva, Juan Luiz Coelho da ; Weinhäuser, Isabel ; Franca-Neto, Pedro Luis; Silveira, Douglas R. A.; Lima, Marinus M.; Schuringa, Jan Jacob ; Koury, Luisa C.; Melo, Raul Antonio Morais; Bittencourt, Rosane; Pagnano, Katia B.; Nunes, Elenaide C.; Fagundes, Evandro Maranhão ; Kerbauy, Fabio R.; Pontes, Lorena Lôbo Figueiredo ; Rego, Eduardo Magalhães
Source: Blood. Conference titles: ASH Annual Meeting Abstracts. Unidades: FMRP, FM
Subjects: DNA MITOCONDRIAL, LEUCEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ARAUJO, Antônio Roberto Lucena de et al. Clinical Signicance of Mitochondrial DNA Content in Acute Promyelocytic Leukemi. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1182/blood-2021-151265. Acesso em: 26 abr. 2026. , 2021
APA
Araujo, A. R. L. de, Martins, D. A. P., Silva, J. L. C. da, Weinhäuser, I., Franca-Neto, P. L., Silveira, D. R. A., et al. (2021). Clinical Signicance of Mitochondrial DNA Content in Acute Promyelocytic Leukemi. Blood. Washington: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1182/blood-2021-151265
NLM
Araujo ARL de, Martins DAP, Silva JLC da, Weinhäuser I, Franca-Neto PL, Silveira DRA, Lima MM, Schuringa JJ, Koury LC, Melo RAM, Bittencourt R, Pagnano KB, Nunes EC, Fagundes EM, Kerbauy FR, Pontes LLF, Rego EM. Clinical Signicance of Mitochondrial DNA Content in Acute Promyelocytic Leukemi [Internet]. Blood. 2021 ; 138 3474-3475.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2021-151265
Vancouver
Araujo ARL de, Martins DAP, Silva JLC da, Weinhäuser I, Franca-Neto PL, Silveira DRA, Lima MM, Schuringa JJ, Koury LC, Melo RAM, Bittencourt R, Pagnano KB, Nunes EC, Fagundes EM, Kerbauy FR, Pontes LLF, Rego EM. Clinical Signicance of Mitochondrial DNA Content in Acute Promyelocytic Leukemi [Internet]. Blood. 2021 ; 138 3474-3475.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1182/blood-2021-151265
Artigo de periodico
HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate (2020)
Ruckert, Mariana Tannús ; Brouwers-Vos, Annet Z.; Nagano, Luis Fernando ; Schuringa, Jan Jacob; Silveira, Vanessa da Silva
Source: Cancer Gene Therapy. Unidade: FMRP
Subjects: LEUCEMIA MIELOIDE AGUDA, PROLIFERAÇÃO CELULAR, DIFERENCIAÇÃO CELULAR, CÉLULAS-TRONCO, HEMATOPOESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RUCKERT, Mariana Tannús et al. HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate. Cancer Gene Therapy, v. 27, n. 11-12, p. 830-833, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41417-020-0198-3. Acesso em: 26 abr. 2026.
APA
Ruckert, M. T., Brouwers-Vos, A. Z., Nagano, L. F., Schuringa, J. J., & Silveira, V. da S. (2020). HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate. Cancer Gene Therapy, 27( 11-12), 830-833. doi:10.1038/s41417-020-0198-3
NLM
Ruckert MT, Brouwers-Vos AZ, Nagano LF, Schuringa JJ, Silveira V da S. HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate [Internet]. Cancer Gene Therapy. 2020 ; 27( 11-12): 830-833.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1038/s41417-020-0198-3
Vancouver
Ruckert MT, Brouwers-Vos AZ, Nagano LF, Schuringa JJ, Silveira V da S. HUWE1 cooperates with RAS activation to control leukemia cell proliferation and human hematopoietic stem cells differentiation fate [Internet]. Cancer Gene Therapy. 2020 ; 27( 11-12): 830-833.[citado 2026 abr. 26 ] Available from: https://doi.org/10.1038/s41417-020-0198-3

USP Schools

ReP

Filtros

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Conference titles

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration